Acute Lymphoblastic Leukemia Therapeutics Market Expansion to be Persistent During 2026 And Market Leaders Would Be : Pfizer Inc., Novartis Pharmaceuticals, Genzyme Corporation, GlaxoSmithKline Plc., ERYTECH Pharma, Talon Therapeutic, Inc.

Acute lymphoblastic leukemia (ALL) is a type of cancer affecting the bone marrow and blood. The condition is characterized by overproduction of immature white blood cells, also known as lymphoblast. The immature or abnormal cells are unable to function properly and build up around the healthy cells. Patients diagnosed with ALL are highly susceptible to recurrent infections, anemia, bleeding and bruising easily as the bone marrow is unable to form adequate numbers of red blood cells, white blood cells, and platelets. The cancer is characterized with high progression rate, and can be fatal if not treated within few months. The cancerous cells have the potential to spread to other organs of the body including lymph nodes, liver, spleen, and the central nervous system. The common symptoms of the condition include renal failure, pneumonia, respiratory distress, and bone pain. Acute lymphocytic leukemia is the most common type of cancer in children, where timely treatment and diagnosis results in efficient cure of the condition.

Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1606

Increasing incidence of acute lymphoblastic leukemia coupled with rising association of the disease with genetic disorders such as Down syndrome in children is a major factor augmenting the market growth. According to the Healthline Media UK Ltd., 2017, ALL accounts for 80% of childhood leukemia and is the most common type of cancer and leukemia in children under 5 years of age than in adults, mostly affecting children aged 2 to 3 years. Also, according to survey by MedicineNet, a medical information portral, about two-thirds of acute leukemia diagnosed in children are associated with Down syndrome, thus increasing the likelihood of children affected with genetic disorders to develop ALL. Furthermore, factors such as high exposure to toxins- benzene and radiations such as X-rays before birth are expected to increase risk of developing ALL and this is expected to propel demand for treatment of the disease using various therapeutics. Therefore, this is expected to aid in growth of the market.

Furthermore, increasing approval of novel treatments such as immune cell gene therapy to treat the condition is also expected to aid in growth of the global acute lymphoblastic lymphoma market. For instance, in August 2017, the U.S. Food and Drug Administration approved chimeric antigen receptor T cell (CAR-T) therapy, Kymriah (tisagenlecleucel) manufactured by Novartis Pharmaceuticals Corporation. The therapy is indicated for patients up to 25 years of age with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Competitive Analysis

Key players operating in the global acute lymphoblastic leukemia therapeutics market include Novartis Pharmaceuticals, Pfizer Inc., Genzyme Corporation, GlaxoSmithKline Plc., ERYTECH Pharma, Talon Therapeutic, Inc., Sigma-Tau Pharmaceuticals, Inc., Spectrum Pharmaceuticals, Inc. F. Hoffmann-La Roche Ltd., Biogen Idec, Inc., Bristol-Myers Squibb, and Celgene Corporation.

Speak to Analyst Before Purchase This Report: https://www.coherentmarketinsights.com/insight/talk-to-analyst/1606

Market Taxonomy

On the basis of drug type, global acute lymphoblastic leukemia therapeutics market is segmented into:

Chemotherapy Drugs : Nelarabine (Arranon), Blinatumomab (Blincyto), Clofarabine (Clolar), Erwinia (Erwinase), Pegaspargase (Oncaspar), Vincristine (Marqibo), Others.

Immunotherapy Drugs : Tisagenlecleucel (Kymriah), Targeted Therapy Drugs, Imatinib (Gleevec), Dasatinib (Sprycel), Nilotinib (Tasigna), Others.

On the basis of indication, global acute lymphoblastic leukemia therapeutics market is segmented into:

Precursor B Cell ALL,
Mature B Cell ALL,
Precursor T Cell ALL.

On the basis of distribution channel, the global acute lymphoblastic leukemia therapeutics market is segmented into:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

On the basis of region, the global acute lymphoblastic leukemia therapeutics market is segmented into:

North America
Latin America
Europe
Asia Pacific
Middle East
Africa

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentMarketinsights.com

This release was published on openPR.